XML 116 R39.htm IDEA: XBRL DOCUMENT
v3.26.1

List of subsidiaries | 12 Months Ended
--- | ---
Dec. 31, 2025
Disclosure of subsidiaries [abstract] |
List of subsidiaries | List of subsidiaries The following list contains the material subsidiaries of the Group at December 31, 2025 and 2024 are as follows:
Name of subsidiaries |  | Place of incorporation/ operation |  | Issued and fully paid share capital |  | Proportion of nominal value of issue capital held by the Company |  | Principal activities
|  |  |  |  |  | 2025 |  | 2024 |  |
|  |  |  |  |  | Directly |  | Indirectly |  | Directly |  | Indirectly |  |
|  |  |  |  |  | % |  | % |  | % |  | % |  |
Prenetics Limited |  | Hong Kong |  | HK$415,276,716 |  | — |  |  | 100 |  |  | — |  |  | 100 |  |  | Genetic and diagnostic health testing
Europa Partners Holdings, LLC (note 33) |  | The United States |  | GBP11.00 |  | — |  |  | 100 |  |  | — |  |  | 100 |  |  | Provision of fulfillment and distribution services of sports nutrition products
IM8 Group Holding Company |  | Cayman Islands |  | $1 |  | 100 |  |  | — |  |  | 100 |  |  | — |  |  | Sales of consumer health products
IM8 (US) LLC |  | The United States |  | n/a |  | 100 |  |  | — |  |  | 100 |  |  | — |  |  | Sales of consumer health products
IM8 Limited |  | Hong Kong |  | HK$1 |  | 100 |  |  | — |  |  | 100 |  |  | — |  |  | Sales of consumer health products
ACT Genomics Holdings Company Limited |  | Cayman Islands |  | $16,713 |  | — |  |  | — |  |  | 73.27 |  |  | — |  |  | Precise cancer genetic testing services
ACT Genomics Co., Ltd. |  | Taiwan |  | TWD455,080,000 |  | — |  |  | — |  |  | — |  |  | 73.21 |  |  | Precise cancer genetic testing - services
ACT Genomics (Hong Kong) Limited |  | Hong Kong |  | HK$775,000 |  | — |  |  | — |  |  | — |  |  | 73.27 |  |  | Precise cancer genetic testing - services
Sanomics Limited |  | Hong Kong |  | HK$500,000 |  | — |  |  | — |  |  | — |  |  | 73.27 |  |  | Precise cancer genetic testing - services
MC Diagnostics Limited |  | United Kingdom |  | GBP1,164 |  | — |  |  | — |  |  | — |  |  | 73.27 |  |  | Sales of medical diagnostics products

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 75 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph B4 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2025-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 75 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration